Industry news that matters to you.  Learn more

Parkinsonian Disorder Differentiation Using Blood Biomarker

A blood biomarker, neurofilament light chain (NfL), may help differentiate between Parkinson’s disease (PD) and atypical parkinsonian disorders (APD), according to a study published in Neurology.

The Michael J. Fox Foundation for Parkinson’s Research Announces Study to Measure Parkinson’s Protein throughout Body

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has launched the observational Systemic Synuclein Sampling Study (S4) to investigate the protein alpha-synuclein as a biomarker of Parkinson’s disease (PD). The study aims to determine in which biofluids and tissues researchers should measure alpha-synuclein to diagnose PD, track progression and evaluate the impact of therapies with the potential to slow or stop disease progression.

Leading Research Funders Build On Global Initiative With New Nearly $2 Million Commitment To Study Commonalities Of Neurodegenerative Diseases

Together, leading funders of research in the U.S., Canada and U.K. are advancing a global funding initiative aimed at better understanding the similarities and differences between progressive brain-deteriorating diseases, such as Alzheimer’s and Parkinson’s, with an expanded partnership and increased funding.

KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson’s Disease, and Diabetic Neuropathy

KineMed, Inc. recently announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: “Compositions and Methods of Treatment Using Modulators of Motoneuron Disease.” The patent allowance covers the treatment of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, Parkinson’s disease, and diabetic neuropathy using the microtubule target modulating agent, noscapine, alone or in combination with a variety of other agents.

The Michael J. Fox Foundation and Intel Join Forces to Improve Parkinson’s Disease Monitoring and Treatment through Advanced Technologies

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Intel Corporation recently announced a collaboration aimed at improving research and treatment for Parkinson’s disease — a neurodegenerative brain disease second only to Alzheimer’s in worldwide prevalence. The collaboration includes a multiphase research study using a new big data analytics platform that detects patterns in participant data collected from wearable technologies used to monitor symptoms. This effort is an important step in enabling researchers and physicians to measure progression of the disease and to speed progress toward breakthroughs in drug development.